Nasdaq

Regeneron Advances Allergy Pipeline with Two Positive Phase 3 Trials Evaluating First-in-Class Antibody-Blockers of Cat and Birch Allergies

TARRYTOWN, N.Y., Sept. 08, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced results evaluating its first-in-class investigational allergen-blocking antibodies in ...
Monthly Prescribing Reference

Allergen-Specific Antibodies Alleviate Ocular Itch in Cat, Birch Pollen Allergy Trials

REGN1908-1909 and REGN5713-5715 significantly reduced ocular itch, conjunctival redness, and skin prick reactivity in adults with cat or birch pollen allergy, respectively. Allergen-blocking ...
Hosted on MSN

Regeneron’s cat and birch allergy mAbs score in Phase III trials

Regeneron Pharmaceuticals’ first-in-class investigational allergen-blocking monoclonal antibodies (mAbs) met their primary endpoints in two Phase III trials in adults with moderate-to-severe cat or ...
Seeking Alpha

Regeneron Advances Allergy Pipeline with Two Positive Phase 3 Trials Evaluating First-in-Class Antibody-Blockers of Cat and Birch Allergies

In separate cat and birch allergen-challenge trials, single doses of allergen-specific antibody blockers significantly reduced allergy symptoms compared to placebo Data from these trials will support ...